Webinar-on-demand: Hit discovery for trained immunity and tolerance

Hit discovery against epigenetic targets

Watch this webinar to learn about: 

  • Trained immunity.
  • The role of epigenetic targets in trained immunity.
  • Hit discovery through ultra-High throughput screening of large libraries.
  • Industry standard H2L biological profiling frameworks.


In this webinar we will focus on epigenetic targets:

  • Center for Open Innovation in Lead Discovery (COILED) is a collaborative drug discovery program focused on epigenetic targets.
  • Modulation of trained innate immunity for treatment of hyper-inflammation and immune deficiency-driven diseases like sepsis and cancer.
  • ultra-High Throughput Screening (uHTS) campaign of 300,000 diverse set of compounds has led to the identification of 3 novel scaffolds (starting points) that progressed into Hit-to-Lead (H2L) phase.


About the presenter:
Dr. Saman Honarnejad – Director Drug Discovery at Pivot Park Screening Centre is a biotechnologist with over a decade of experience in High Throughput Biology. At Pivot Park Screening Centre (PPSC) in Oss, the Netherlands, he is involved in cellular and biochemical assay development, ultra-High Throughput screening (uHTS) and Hit-to-Lead (H2L) biological compound profiling within a wide range of commercial, academic and public-private partnership projects including the European Lead Factory (ELF).

Prior to joining PPSC in 2017, he was active in high-content compound profiling method development at Max-Planck Institute (Germany), Harvard Medical School (United States) and Heidelberg University (Germany) and further optimized microarray-based cDNA/RNAi functional screening assays at the European Molecular Biology Laboratory (EMBL).

(This webinar will be during 30 minutes)

Thank you for you interest!

To download this webinar we would like to receive your e-mail.